Effects of 4-aminopyridine in patients with multiple sclerosis

J Neurol Sci. 1983 Aug-Sep;60(3):353-62. doi: 10.1016/0022-510x(83)90145-4.

Abstract

4-Aminopyridine (4-AP) was administered to two groups of patients with multiple sclerosis (MS). The first group consisted of 5 patients with labile visual symptoms, 2 of whom had arcuate scotomata. 4-AP improved visual performance of most patients in this group and reduced the size of scotomata. The second group consisted of 5 patients with the spinal form of MS who were in a stable state; in this group 4-AP had little effect clinically or on tests of visual function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine
  • Adult
  • Aged
  • Aminopyridines / therapeutic use*
  • Differential Threshold
  • Evoked Potentials, Visual / drug effects
  • Humans
  • Light
  • Middle Aged
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Scotoma / drug therapy
  • Vision Disorders / drug therapy
  • Vision Disorders / etiology

Substances

  • Aminopyridines
  • 4-Aminopyridine